You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

139 search results for: type 2 inflammation

<b>Type</b> <b>2</b> <b>Inflammation</b> Mediates Severe Asthma in Pediatric Patients

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Blisters and Beyond: Autoimmunity Meets <b>Type</b> <b>2</b> <b>Inflammation</b> in Bullous Pemphigoid

expert video

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

12 min

Dermatology

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms

<b>Type</b> <b>2</b> <b>Inflammation</b> Is a Significant Driver of Pediatric Severe Asthma

Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

Managing <b>Type</b> <b>2</b> Inflammatory Diseases: Multidisciplinary Frame of Mind

expert video

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

6 min

Type 2 Inflammation

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation

ADVENT On Air | Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in COPD

Podcast

ADVENT On Air | Role of Type 2 Inflammation in COPD

21 min

Pulmonology

Drs Stephanie Christenson and Jean Bourbeau explore the role of type 2 inflammation in Chronic Obstructive Pulmonary Disease (COPD).

FeNO: A Biomarker of <b>Type</b> <b>2</b> <b>Inflammation</b> in Pediatric Asthma Patients

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma

Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Dermatology

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

expert video

Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

2 min

Dermatology

Join Professor Hide as he describes the potential role of Type 2 inflammation in the pathogenesis of CSU.

Why targeting <b>Type</b> <b>2</b> <b>Inflammation</b> is important in the treatment of skin diseases like AD, PN and CSU

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

5 min

Type 2 Inflammation

Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases

Skin Barrier Dysfunction and <b>Type</b> <b>2</b> <b>Inflammation</b> in Atopic Dermatitis

videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

5 min

Dermatology

Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis

Understanding the Pathophysiology of Pediatric <b>Type</b> <b>2</b> Inflammatory Diseases

expert video

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases

10 min

Type 2 Inflammation

Prof. Oscar Palomares discusses the underlying pathophysiology of type 2 inflammation in pediatric patients with AD, asthma, or EoE.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ItalyChange country/region